NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.
Workspace · Cancer algorithms · Vulva
Vulva · 7,130 new · 1,750 deaths (ACS 2026) · mortality 0.6 per 100k · 5-yr RS 69.7% (SEER)
Mortality 0.6 per 100k (SEER / ACS common-sites). Never an artboard percent.
Lifetime ≈ 0.3% among women (SEER Stat Facts). The official page has no 2023 living count — not invented. No encoded screening interval.
Median age at diagnosis 70 · at death 76 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.
Incidence women 2.6 per 100k · mortality women 0.6 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.
Most often diagnosed among women aged 65–74. Deaths highest among women aged 75–84. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.
New cases rising 0.6% each year (2014–2023). Death rates rising 1.9% each year (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval.
Highest new-case rate: Non-Hispanic American Indian/Alaska Native women 3.6 per 100k. Highest death rate: Non-Hispanic American Indian/Alaska Native women 0.7 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
Race/ethnicity rates per 100k (SEER Stat Facts)
| Group | Inc. men | Inc. women | Deaths men | Deaths women |
|---|---|---|---|---|
| Hispanic | — | 1.9 | — | 0.4 |
| Non-Hispanic American Indian/Alaska Native | — | 3.6 | — | 0.7 |
| Non-Hispanic Asian/Pacific Islander | — | 1.1 | — | 0.2 |
| Non-Hispanic Black | — | 1.9 | — | 0.4 |
| Non-Hispanic White | — | 3.1 | — | 0.7 |
Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
USPSTF screening pointer
No USPSTF population-screening recommendation is cited for this stub.
ACS / SEER pin only. Not encoded. Not a screening recommendation.
ACS early-detection pointer
ACS 2025 · People considering vulvar-cancer early detection · ACS (2025): there is no standard screening for this disease. Well-woman exams are named; they are not encoded as a vulvar-cancer interval.
Cited ACS statement only. Not a screening engine. ACS-vulva-detect
Surveillance pointer
ACS-vulva-follow 2025 · cited only · ACS living-as-a-survivor page names typical surveillance with physical exam, bloodwork, and possibly imaging. ACS names typical cadences; those months are not encoded. Not a vulvar-exam engine.
Named public source only. Not a personal follow-up calendar. ACS-vulva-follow
Surveillance pointer
ACS-vulva-follow 2025 · cited only · ACS living-as-a-survivor page names later cancers after vulvar-cancer treatment, including a second vulvar cancer, anal, vaginal, mouth and throat, larynx, lung, and brain or CNS. Many are linked to smoking or HPV. Named later-cancer sites are not encoded. Additional testing to look for second cancers in women without symptoms is not recommended. Complementary to the living-as pointer. Not an HPV-dose, anal-Pap, or ASCCP engine. Not a second-primary screening engine.
Named public source only. Not a personal follow-up calendar. ACS-vulva-follow
Surveillance pointer
ACS-long-term-effects 2025 · cited only · ACS long-term page names low estrogen after pelvic radiation or hormone-blocking medicines, plus osteopenia or osteoporosis and lymphedema after node surgery or radiation. Those names are not encoded. Complementary to the living-as pointer. Not a DXA-interval, HPV-dose, anal-Pap, or ASCCP engine.
Named public source only. Not a personal follow-up calendar. ACS-long-term-effects
Surveillance pointer
ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names a treatment summary and survivorship care plan, plus watching for recurrence and for a second cancer. Those plans are not encoded. Complementary to the GYN printout. GTD stays out of domain. Not an HPV-dose, anal-Pap, or ASCCP engine.
Named public source only. Not a personal follow-up calendar. ACS-follow-up-care
Toxicity pointer
ACS-vulva-follow 2025 · empty on purpose · ACS living-as-a-survivor page names treatment side effects. Those late effects are not encoded. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-vulva-follow
Toxicity pointer
ACS-vulva-follow 2025 · empty on purpose · ACS living-as-a-survivor page names later cancers after vulvar-cancer treatment. Those second-cancer risks are not encoded. Complementary to the living-as pointer. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-vulva-follow
Toxicity pointer
ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later low estrogen, osteoporosis, and lymphedema after pelvic treatment or node surgery. Those late effects are not encoded. Complementary to the living-as pointer. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-long-term-effects
Toxicity pointer
ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names a treatment summary and second-cancer watching after pelvis treatment. Those named tests are not encoded. Complementary to the GYN printout. GTD stays out of domain. Not an HPV-dose, anal-Pap, or ASCCP engine. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-follow-up-care
Late toxicity printout
Late toxicity printout — GYN
Acute: ACS names fatigue, pelvic-field skin change, short-term rectal and bladder problems, nausea, and vaginal or vulvar field irritation. Late: radiation proctitis and cystitis, incontinence, fistula, menopause symptoms, fertility effects, low estrogen, osteoporosis, lymphedema, lasting fatigue, jaw osteonecrosis after bisphosphonates, and vision change after hormone therapy. Monitor: pelvic bleeding, pain, or leakage after RT; regular cervical screening may be named; lasting fatigue or sleep problems; dental check before bisphosphonates; vision change after hormone therapy; a treatment summary. Those names are not encoded. GTD stays out of domain. First-row cervix toxicity stays empty on purpose. Not a CA-125, HPV-dose, or ASCCP engine.
Questions to ask
ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.
ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.
ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.
Treatment summary and care plan
ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.
How late effects are managed
ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.
ACS long-term late names
Named conditions to monitor
Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Adult GYN RT fields only. Gestational trophoblastic disease is out of domain. Complementary ACS long-term page is named, not encoded. Not a CA-125 or ASCCP engine. No invented trial percent.
Open GYN printout →NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.
algo-stub-vulva · stub · none · v2-stub-vulva
SEER 5-year relative survival by stage (cited stub)
Localized 85.5% · Regional 51.4% · Distant 20.8% · All 69.7%
Female site. No 2023 living count on the official page.
Percent of cases by stage (SEER Stat Facts)
Localized 58% · Regional 27% · Distant 8% · Unknown 7%
Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage. Female site.
lifetime
Vulva birth-to-death (women)
≈ 0.3%
Screening · Surveillance · Toxicity on four golden fixtures
Rio · Plan — survivor
not computed — v2 stubCited ACS/SEER population pin only
screening
ACS — no standard vulvar-cancer screen
Cited ACS 2025 statement only. Well-woman exams are not an encoded interval.
not encoded
surveillance
ACS follow-up cited — vulva months not encoded
Cited ACS living-as-a-survivor page only. Not a vulvar-exam engine.
not encoded
toxicity
ACS late effects cited — vulva months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded
Noah · Plan — skin cancer
not computed — v2 stubCited ACS/SEER population pin only
screening
ACS — no standard vulvar-cancer screen
Cited ACS 2025 statement only. Well-woman exams are not an encoded interval.
not encoded
surveillance
ACS follow-up cited — vulva months not encoded
Cited ACS living-as-a-survivor page only. Not a vulvar-exam engine.
not encoded
toxicity
ACS late effects cited — vulva months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded
Walter · S1 prostate
not computed — v2 stubCited ACS/SEER population pin only
screening
ACS — no standard vulvar-cancer screen
Cited ACS 2025 statement only. Well-woman exams are not an encoded interval.
not encoded
surveillance
ACS follow-up cited — vulva months not encoded
Cited ACS living-as-a-survivor page only. Not a vulvar-exam engine.
not encoded
toxicity
ACS late effects cited — vulva months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded
Priya · average-risk
not computed — v2 stubCited ACS/SEER population pin only
screening
ACS — no standard vulvar-cancer screen
Cited ACS 2025 statement only. Well-woman exams are not an encoded interval.
not encoded
surveillance
ACS follow-up cited — vulva months not encoded
Cited ACS living-as-a-survivor page only. Not a vulvar-exam engine.
not encoded
toxicity
ACS late effects cited — vulva months not encoded
Empty on purpose. Named ACS side effects are not encoded.
not encoded
Not implemented. Cited public snapshot only. Not a screening recommendation. Mortality is a rate per 100k, not an artboard percent.